The Federal Trade Commission has struck out so far in trying to block drug companies from reaching settlements it fears are slowing the introduction of generic competitors, but the head of the agency said she won’t stop fighting to end such deals.

FTC Chairman Deborah Platt Majoras said she’s concerned payments by brand name drug makers to their generic rivals may be nothing more than payoffs to keep cheap drugs off the market, depriving consumers of low-cost medicines.